Author of the publication

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group

, , , , , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL), , , , , , , , , and 5 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19 (3): 545–552 (2008)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF, , , , , , , , , and 3 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 23 (5): 1267–1273 (2012)Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, , , , , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, , , , , , , , , and 3 other author(s). Blood, 104 (3): 634–641 (2004)Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia, , , , , , , , , and 3 other author(s). Blood, 117 (10): 2918–2923 (2011)Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma, , , , , , , , , and 1 other author(s). Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (13): 3637–3647 (2012)Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL, , , , , and . Annals of hematology, (2001)Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL), , , , , , , , , and . Leukemia, 22 (12): 2226–2229 (2008)Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone, , , , , , , , , and 19 other author(s). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 (11): 2905–2914 (2001)